Latest Insider Transactions at Zymeworks Inc. (ZYME)
This section provides a real-time view of insider transactions for Zymeworks Inc. (ZYME). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zymeworks Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zymeworks Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2022
|
Neil Josephson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,475
-14.62%
|
$19,800
$8.1 P/Share
|
|
Nov 10
2022
|
Neil Josephson Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,885
+25.8%
|
-
|
|
Jul 05
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,525
+9.34%
|
$6,100
$4.51 P/Share
|
|
Jul 05
2022
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,525
+12.14%
|
$6,100
$4.51 P/Share
|
|
Mar 10
2022
|
Neil Josephson Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,395
+11.7%
|
-
|
|
Mar 10
2022
|
Neil A Klompas Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,979
-18.33%
|
$17,874
$6.88 P/Share
|
|
Mar 10
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+14.93%
|
-
|
|
Jan 07
2022
|
Neil Josephson Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+31.02%
|
$70,000
$14.28 P/Share
|
|
Jan 07
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
277
+2.45%
|
$3,601
$13.94 P/Share
|
|
Jan 07
2022
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.2%
|
$962
$13.94 P/Share
|
|
Jan 07
2022
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65
+2.98%
|
$845
$13.94 P/Share
|
|
Aug 31
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,900
+11.88%
|
$73,500
$15.0 P/Share
|
|
Jul 16
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,191
-13.66%
|
$1,482,876
$36.0 P/Share
|
|
Jul 16
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,191
+12.02%
|
$164,764
$4.26 P/Share
|
|
Jul 15
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,800
-1.44%
|
$136,800
$36.0 P/Share
|
|
Jul 15
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+1.42%
|
$15,200
$4.27 P/Share
|
|
Jul 12
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,669
-4.64%
|
$456,084
$36.12 P/Share
|
|
Jul 12
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,669
+4.43%
|
$50,676
$4.31 P/Share
|
|
Jul 06
2021
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
461
+18.33%
|
$13,369
$29.49 P/Share
|
|
Jul 06
2021
|
James Priour Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
510
+16.87%
|
$14,790
$29.49 P/Share
|
|
Jul 06
2021
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
299
+2.7%
|
$8,671
$29.49 P/Share
|
|
Jul 06
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.42%
|
$13,166
$29.49 P/Share
|
|
Jul 06
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
510
+7.43%
|
$14,790
$29.49 P/Share
|
|
Apr 13
2021
|
James Priour Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
950
-32.17%
|
$25,650
$27.93 P/Share
|
|
Apr 13
2021
|
James Priour Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,266
+43.42%
|
-
|
|
Mar 15
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
837
+12.54%
|
$28,458
$34.24 P/Share
|
|
Mar 15
2021
|
Kathryn O'Driscoll Chief People Officer |
SELL
Open market or private sale
|
Direct |
786
-13.58%
|
$26,724
$34.72 P/Share
|
|
Mar 10
2021
|
Neil A Klompas Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,425
-11.98%
|
$48,450
$34.95 P/Share
|
|
Mar 10
2021
|
Neil A Klompas Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+17.37%
|
-
|
|
Mar 10
2021
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,048
-16.31%
|
$35,632
$34.95 P/Share
|
|
Mar 10
2021
|
Diana Hausman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+28.01%
|
-
|
|
Mar 10
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,392
-1.66%
|
$149,328
$34.95 P/Share
|
|
Mar 10
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,708
+2.83%
|
-
|
|
Mar 10
2021
|
Anthony J. Polverino Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,048
-3.27%
|
$35,632
$34.95 P/Share
|
|
Mar 10
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.24%
|
-
|
|
Mar 10
2021
|
Kathryn O'Driscoll Chief People Officer |
SELL
Open market or private sale
|
Direct |
568
-8.94%
|
$19,312
$34.95 P/Share
|
|
Mar 10
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,354
+17.56%
|
-
|
|
Feb 12
2021
|
Kathryn O'Driscoll Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,083
+29.4%
|
$70,822
$34.24 P/Share
|
|
Jan 08
2021
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
284
+2.93%
|
$8,520
$30.92 P/Share
|
|
Jan 07
2021
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
207
+5.01%
|
$6,210
$30.92 P/Share
|
|
Jan 07
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48
+0.16%
|
$1,440
$30.92 P/Share
|
|
Dec 09
2020
|
Neil A Klompas Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-73.27%
|
$1,325,000
$53.25 P/Share
|
|
Dec 09
2020
|
Neil A Klompas Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+32.57%
|
$100,000
$4.93 P/Share
|
|
Dec 07
2020
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
850
-1.51%
|
$47,600
$56.16 P/Share
|
|
Dec 04
2020
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,032
-61.87%
|
$331,760
$55.12 P/Share
|
|
Dec 04
2020
|
Diana Hausman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,032
+27.43%
|
$60,320
$10.83 P/Share
|
|
Dec 02
2020
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
701
-15.86%
|
$38,555
$55.01 P/Share
|
|
Dec 02
2020
|
Diana Hausman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
701
+7.35%
|
$7,010
$10.83 P/Share
|
|
Dec 01
2020
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,267
-83.09%
|
$1,004,685
$55.19 P/Share
|
|
Dec 01
2020
|
Diana Hausman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,267
+36.8%
|
$182,670
$10.83 P/Share
|